{"pmid":32277907,"title":"Recommendations from national regulatory agencies for ongoing cancer trials during the COVID-19 pandemic.","text":["Recommendations from national regulatory agencies for ongoing cancer trials during the COVID-19 pandemic.","Lancet Oncol","de Paula, Bruno H R","Araujo, Indiara","Bandeira, Livia","Barreto, Nathalia M P B","Doherty, Gary J","32277907"],"journal":"Lancet Oncol","authors":["de Paula, Bruno H R","Araujo, Indiara","Bandeira, Livia","Barreto, Nathalia M P B","Doherty, Gary J"],"date":"2020-04-12T11:00:00Z","year":2020,"_id":"32277907","week":"202015|Apr 06 - Apr 12","doi":"10.1016/S1470-2045(20)30226-6","source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1663798882965913600,"score":7.9164424,"similar":[{"pmid":32278730,"title":"Ongoing Lessons During the COVID-19 Pandemic.","text":["Ongoing Lessons During the COVID-19 Pandemic.","J Am Coll Surg","Ong, Chong Yau","32278730"],"journal":"J Am Coll Surg","authors":["Ong, Chong Yau"],"date":"2020-04-13T11:00:00Z","year":2020,"_id":"32278730","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.jamcollsurg.2020.04.005","source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1663890921964437505,"score":53.724358},{"pmid":32242116,"title":"African nations missing from coronavirus trials.","text":["African nations missing from coronavirus trials.","Nature","Roussi, Antoaneta","Maxmen, Amy","32242116"],"journal":"Nature","authors":["Roussi, Antoaneta","Maxmen, Amy"],"date":"2020-04-04T11:00:00Z","year":2020,"_id":"32242116","week":"202014|Mar 30 - Apr 05","doi":"10.1038/d41586-020-01010-7","keywords":["Developing world","Health care","Infection","Virology"],"source":"PubMed","locations":["African"],"topics":["General Info"],"weight":1,"_version_":1663352135802159105,"score":49.289597},{"pmid":32247821,"title":"3CL(pro) inhibitors as a potential therapeutic option for COVID-19: Available evidence and ongoing clinical trials.","text":["3CL(pro) inhibitors as a potential therapeutic option for COVID-19: Available evidence and ongoing clinical trials.","Pharmacol Res","Sisay, Mekonnen","32247821"],"journal":"Pharmacol Res","authors":["Sisay, Mekonnen"],"date":"2020-04-06T11:00:00Z","year":2020,"_id":"32247821","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.phrs.2020.104779","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1663352136183840769,"score":43.37875},{"pmid":32125132,"title":"[Expert recommendations on the management of patients with advanced non-small cell lung cancer during epidemic of COVID-19 (Trial version)].","text":["[Expert recommendations on the management of patients with advanced non-small cell lung cancer during epidemic of COVID-19 (Trial version)].","The outbreak of coronavirus disease 2019 (COVID-19) has become a public health emergency of major international concern. Given the systemic immunosuppressive state caused by malignancy and anticancer treatments, patients with advanced lung cancer may be at a higher risk of COVID-19 infection. During epidemic of COVID-19, a guideline for the optimal management of patients with advanced lung cancer urgently needs to be proposed to distinguish the symptoms of COVID-19 and the side effects of antitumor drugs. This network questionnaire survey was conducted on the lung cancer group of the Chinese Thoracic Society, Chinese Medical Association; the lung cancer group of the Chinese Society of Clinical Oncology Youth Committee; and the Chinese Respiratory Oncology Collaboration. 321 valid questionnaires were received. Based on the guidelines on lung cancer and the results of the questionnaires, a consensus was reached. During the epidemic of COVID-19, We recommended that patients with advanced NSCLC should be treated as outpatients as possible at the nearest medical center; Patients who need to be hospitalized for antitumor treatment should be excluded from COVID-19 infection; More intensive attention should be paid to identification of COVID-19-related symptoms and adverse reactions caused by the malignancy or antitumor treatments. Stronger personal protection should be made for advanced NSCLC patients; An intentional postponing of antitumor treatment should be considered according to patient performance status. Treatment strategies should be made according to different types of advanced NSCLC patients and efficacy and toxicity of drugs.","Zhonghua Jie He He Hu Xi Za Zhi","32125132"],"abstract":["The outbreak of coronavirus disease 2019 (COVID-19) has become a public health emergency of major international concern. Given the systemic immunosuppressive state caused by malignancy and anticancer treatments, patients with advanced lung cancer may be at a higher risk of COVID-19 infection. During epidemic of COVID-19, a guideline for the optimal management of patients with advanced lung cancer urgently needs to be proposed to distinguish the symptoms of COVID-19 and the side effects of antitumor drugs. This network questionnaire survey was conducted on the lung cancer group of the Chinese Thoracic Society, Chinese Medical Association; the lung cancer group of the Chinese Society of Clinical Oncology Youth Committee; and the Chinese Respiratory Oncology Collaboration. 321 valid questionnaires were received. Based on the guidelines on lung cancer and the results of the questionnaires, a consensus was reached. During the epidemic of COVID-19, We recommended that patients with advanced NSCLC should be treated as outpatients as possible at the nearest medical center; Patients who need to be hospitalized for antitumor treatment should be excluded from COVID-19 infection; More intensive attention should be paid to identification of COVID-19-related symptoms and adverse reactions caused by the malignancy or antitumor treatments. Stronger personal protection should be made for advanced NSCLC patients; An intentional postponing of antitumor treatment should be considered according to patient performance status. Treatment strategies should be made according to different types of advanced NSCLC patients and efficacy and toxicity of drugs."],"journal":"Zhonghua Jie He He Hu Xi Za Zhi","date":"2020-03-04T11:00:00Z","year":2020,"_id":"32125132","week":"202010|Mar 02 - Mar 08","doi":"10.3760/cma.j.cn112147-20200221-00138","keywords":["Advanced non-small cell lung cancer","COVID-19","Management"],"source":"PubMed","locations":["optimal"],"topics":["Treatment","Diagnosis","Prevention"],"weight":1,"_version_":1663352134282772480,"score":42.340202},{"pmid":32205306,"title":"Covid-19: European drugs agency to review safety of ibuprofen.","text":["Covid-19: European drugs agency to review safety of ibuprofen.","BMJ","Day, Michael","32205306"],"journal":"BMJ","authors":["Day, Michael"],"date":"2020-03-25T11:00:00Z","year":2020,"_id":"32205306","week":"202013|Mar 23 - Mar 29","doi":"10.1136/bmj.m1168","source":"PubMed","locations":["European"],"topics":["General Info"],"weight":1,"e_drugs":["Ibuprofen"],"_version_":1663352133706055680,"score":41.564987}]}